Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 8/20 | 0.55 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.55 |
| ▸ | MTOR | P42345 | 4/20 | 0.50 |
| ▸ | PDCD1 | Q15116 | 12/20 | 0.46 |
| ▸ | CD274 | Q9NZQ7 | 12/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 11/20 | 0.46 |
| ▸ | ATR | Q13535 | 11/20 | 0.46 |
| ▸ | ATRIP | Q8WXE1 | 11/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2487507 | 0.91 | PIK3CA (0.62) | PIK3CAPIK3CDMTORPDCD1CD274 | |
| SCHEMBL738140 | 0.91 | PIK3CA (0.62) | PIK3CAPIK3CDMTORPDCD1CD274 | |
| SCHEMBL2487510 | 0.91 | PIK3CA (0.62) | PIK3CAPIK3CDMTORPDCD1CD274 | |
| SCHEMBL2493212 | 0.87 | PIK3CA (0.51) | PIK3CAPIK3CDMTORPDCD1CD274 | |
| SCHEMBL2493217 | 0.87 | PIK3CA (0.51) | PIK3CAPIK3CDMTORPDCD1CD274 | |
| SCHEMBL3596412 | 0.87 | PIK3CA (0.51) | PIK3CAPIK3CDMTORPDCD1CD274 | |
| SCHEMBL20798042 | 0.87 | PIK3CA (0.51) | PIK3CAPIK3CDMTORPDCD1CD274 | |
| SCHEMBL29026042 | 0.86 | PIK3CA (0.50) | PIK3CAPIK3CDMTORPDCD1CD274 | |
| SCHEMBL29026044 | 0.86 | PIK3CA (0.50) | PIK3CAPIK3CDMTORPDCD1CD274 | |
| SCHEMBL3588755 | 0.85 | PIK3CA (0.49) | PIK3CAPIK3CDMTORPDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9421213-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2016-08-23 | — | — | US | disclosed |
| US-20160074412-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-03-17 | — | — | US | disclosed |
| US-9155742-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-10-13 | — | — | US | disclosed |
| US-20150164908-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2015-06-18 | — | — | US | disclosed |
| US-8999997-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-04-07 | — | — | US | disclosed |
| EP-2579877-B1 | MORPHOLINO PYRIMIDINES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2014-08-13 | — | — | EP | disclosed |
| US-20140018364-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2014-01-16 | — | — | US | disclosed |
| US-8552004-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-10-08 | — | — | US | disclosed |
| EP-2579877-A1 | MORPHOLINO PYRIMIDINES AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2013-04-17 | — | — | EP | disclosed |
| US-20130005725-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2013-01-03 | — | — | US | disclosed |
| US-8252802-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2012-08-28 | — | — | US | disclosed |
| WO-2011154737-A1 | MORPHOLINO PYRIMIDINES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2011-12-15 | — | — | WO | disclosed |
| US-20110306613-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150164908-A1 | Chemical Compounds | CYP2C19, ABCG2, CYP2C9 | PIK3CA 1056/4885PIK3CD 2216/4885MTOR 732/4885 |
| US-20110306613-A1 | CHEMICAL COMPOUNDS | CYP2C19, ABCG2, CYP2C9 | PIK3CA 1056/4885PIK3CD 2216/4885MTOR 732/4885 |
| US-20160074412-A1 | Chemical Compounds | CYP2C19, ABCG2, CYP2C9 | PIK3CA 1056/4885PIK3CD 2216/4885MTOR 732/4885 |
| US-20130005725-A1 | CHEMICAL COMPOUNDS | CYP2C19, ABCG2, CYP2C9 | PIK3CA 1056/4885PIK3CD 2216/4885MTOR 732/4885 |
| US-20140018364-A1 | CHEMICAL COMPOUNDS | CYP2C19, ABCG2, CYP2C9 | PIK3CA 1056/4885PIK3CD 2216/4885MTOR 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.